DUBLIN--(BUSINESS WIRE)--The "Heavy Metal Poisoning - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Heavy Metal Poisoning - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Heavy Metal Poisoning (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Heavy Metal Poisoning (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Heavy Metal Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, IND/CTA Filed and Preclinical stages are 1, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Heavy Metal Poisoning (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Heavy Metal Poisoning (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Heavy Metal Poisoning (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
Introduction
- Report Coverage
Heavy Metal Poisoning - Overview
Heavy Metal Poisoning - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
Heavy Metal Poisoning - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Heavy Metal Poisoning - Companies Involved in Therapeutics Development
- Capture Pharmaceuticals Inc
- EmeraMed Ltd
- Medesis Pharma SA
- PDX Pharmaceuticals LLC
- ZoneOne Pharma Inc
Heavy Metal Poisoning - Drug Profiles
C-2E2 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Deferoxamine mesylate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Emeramide - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Hinokitiol - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
NU-01 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
NU-02 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
PDX-003 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Small Molecule for Heavy Metal Poisoning - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
Heavy Metal Poisoning - Dormant Projects
Heavy Metal Poisoning - Discontinued Products
Heavy Metal Poisoning - Product Development Milestones
- Featured News & Press Releases
- Sep 21, 2018: President presents at the 2018 International Academy of Oral Medicine and Toxicology (IAOMT) symposium
- Sep 21, 2018: President presents at the 2018 International Academy of Oral Medicine and Toxicology (IAOMT) symposium
Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/bb3ko1
